TransMedics Q2 Revenue Beats, But Net Income Drops 58% on Surging R&D Spend; FY26 Guidance Raised
TMDX sits 36% above its 52-week low of $60.105.
Summary
TransMedics reported Q2 revenue of $189.9M (+21% YoY), beating estimates, but net income fell 58% to $14.7M due to a 49% surge in operating expenses. FY26 revenue guidance was raised to $737M-$757M.
Key Events · Earnings and Guidance · TMDX
-
Q2 Revenue Beats, Net Income Misses
Revenue of $189.9M exceeded the $183.64M consensus, but net income fell 58% YoY to $14.7M ($0.41 diluted EPS) as operating expenses surged 49% to $89.5M.
-
FY26 Guidance Raised at Low End
Full-year 2026 revenue guidance increased to $737M-$757M (from $727M-$757M), implying 22-25% growth, excluding PAD Aviation and clinical trial revenue.
-
Margin Compression from Strategic Investments
Operating margin contracted to 12.5% from 23.2% a year ago, driven by planned R&D and infrastructure spending on OCS Kidney, Gen 3.0, and logistics.
-
PAD Aviation Investment Completed
On July 1, 2026, TransMedics completed its strategic investment in PAD Aviation, a German private aviation operator, to build a dedicated organ transplant air logistics network in Europe.
Analysis · TMDX · Industrial Applications And Services
Record Q2 revenue of $189.9 million topped consensus, yet net income tumbled to $14.7 million as operating expenses surged 49%—a reflection of heavy investment in OCS Kidney, Gen 3.0, and clinical programs. While the company raised the low end of its full-year revenue guidance to $737 million, signaling confidence in demand, margin compression is the clear trade-off. Adding a governance overhang, the concurrent 10-Q disclosed a material weakness in internal controls.
At the time of this filing, TMDX was trading at $82.01 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $60.11 to $156.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.